Influence of the rs1080985 Single Nucleotide Polymorphism of the CYP2D6 Gene and APOE Polymorphism on the Response to Donepezil Treatment in Patients with Alzheimer's Disease in China

Mengyuan Liu; Ying Zhang; Ya Ruth Huo; Shuling Liu; Shuai Liu; Junwei Wang; Change Wang; Jinhuan Wang; Yong Ji

doi:10.1159/000367596

Influence of the rs1080985 Single Nucleotide Polymorphism of the CYP2D6 Gene and APOE Polymorphism on the Response to Donepezil Treatment in Patients with Alzheimer's Disease in China

Dement Geriatr Cogn Dis Extra. 2014 Nov 15;4(3):450-6. doi: 10.1159/000367596. eCollection 2014 Sep.

Authors

Mengyuan Liu¹, Ying Zhang², Ya Ruth Huo³, Shuling Liu², Shuai Liu², Junwei Wang⁴, Change Wang⁴, Jinhuan Wang⁴, Yong Ji²

Affiliations

¹ Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin, China ; Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin, China ; Tianjin Neurosurgery Institute, Tianjin Huanhu Hospital, Tianjin, China.
² Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin, China ; Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin, China.
³ School of Medicine, University of New South Wales, Kensington, N.S.W., Australia.
⁴ Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases, Tianjin, China ; Tianjin Neurosurgery Institute, Tianjin Huanhu Hospital, Tianjin, China.

Abstract

Background/aim: Recent data have indicated that the rs1080985 single nucleotide polymorphism (SNP) of the cytochrome P450 (CYP) 2D6 and the common apolipoprotein E (APOE) gene may affect the response to donepezil in patients with Alzheimer's disease (AD). We investigated this association in Chinese patients with mild-to-moderate AD.

Methods: In this prospective cohort study, analyses of CYP2D6 and APOE were conducted in 208 native Chinese patients with mild-to-moderate AD. All patients were treated with donepezil 5 mg/day for 6 months, and the response to treatment was assessed using the Mini-Mental State Examination.

Results: No significant differences between responders (68.9%) and nonresponders (31.1%) to donepezil treatment (6 months' duration) were observed in the distribution of the CYP2D6 rs1080985 SNP, common APOE polymorphism or a combination of the two.

Conclusions: Our results suggest that neither the CYP2D6 nor the APOE polymorphism influences the 6-month response to donepezil treatment in a Chinese population with AD.

Keywords: APOE; Alzheimer's disease; CYP2D6; Chinese population; Donepezil; Polymorphism.